Jinghua Pharmaceutical Group002349.SZValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 19, 2026, Jinghua Pharmaceutical Group (002349.SZ) trades at a P/E of 29.80x, P/B of 2.37x, P/S of 4.43x, and a dividend yield of 1.12%.
Longitudinal percentile comparison: P/E sits at the 43rd percentile over the trailing 10Y window (vs. 79th percentile over 3Y); P/B sits at the 47th percentile over the trailing 10Y window (vs. 58th percentile over 3Y); P/S sits at the 56th percentile over the trailing 10Y window (vs. 75th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 41st percentile within its industry and the 41st percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.12%, ranking at the 83rd percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 4.4 points of each other — a consistent signal from both angles. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Jinghua Pharmaceutical Group operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHE: 002349 · SZSE: 002349 · 002349
Want the full picture on whether Jinghua Pharmaceutical Group (002349.SZ) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 29.80 | ||||||
| P/B (MRQ) | 2.37 | ||||||
| P/S (TTM) | 4.43 | ||||||
| Dividend Yield | 1.12% | ||||||
| Buyback + Div Yield | 1.12% |